India's pharma space has a new contender. Worth chasing?

Summary: 600 chemical building blocks. 55 countries. A single cancer drug contract that changed everything. Acutaas is making a bet most pharma investors haven't noticed yet, and the numbers so far are hard to ignore.

Something unusual caught our attention at Acutaas. In two years, the company nearly doubled its revenue, pushed operating profit margins from 11 per cent to nearly 29 per cent and returned 85 per cent to shareholders in a single year. That kind of momentum, in a business most investors have never heard of, warranted a closer look.

What we found is a company in the middle of a significant shift—moving away from being a commoditised chemicals supplier toward becoming a specialised contract manufacturer for patented drugs. The ambition is enormous: Rs 1,000 crore from contract manufacturing alone by FY28, roughly what the entire business earns today.

What Acutaas actually does

To understand Acutaas, start at the very beginning of the pharmaceutical supply chain. Every medicine relies on an active ingredient, the chemical that actually treats a condition. Before that ingredient can be made, it has to be assembled from simpler chemical building blocks called intermediates. Acutaas makes these building blocks, over 600 of them, sold across 55 countries. Europe accounts for about two-thirds of revenue, and roughly 85 per cent of the business serves chronic therapies: cancer, heart disease and depression.

The business has three parts.

• The first is generic intermediates, about half of revenue, which supply affordable, off-patent drugmakers like GSK, Cipla, Sun Pharma and Dr Reddy's. The economics here are tough: intense competition and cost-focused buyers keep margins thin.
• The second is the innovator business, which supplies advanced intermediates for patented medicines. Acutaas embeds itself early in a molecule's development so that if the drug eventually gets approved, it is already the chosen supplier. Margins here run 2-3 per cent higher than in generics.
• The third segment, and the one that changes everything, is CDMO, or Contract Development and Manufacturing. Under this model, a pharma company appoints a single specialist manufacturer for each drug molecule, typically for the life of the patent. Once chosen, that manufacturer's specific chemical process gets written into the drug's regulatory approval. Switching to a different supplier later means redoing years of compliance testing, making it extremely unlikely. At roughly 10 per cent of revenue in FY24, CDMO was Acutaas's smallest segment. It is also the one management is racing to build.

Margins fell sharply to 11.2 per cent in FY24 when Chinese manufacturers began dumping final drug products at steep discounts, squeezing Acutaas's customers, who in turn pushed back hard on ingredient costs. Acutaas was forced to shift to spot pricing just to stay competitive.

The recovery to 28.7 per cent today is more than a reversal. The company shifted its generic portfolio toward higher-value molecules, grew CDMO's share of revenue and benefited from operating leverage, the effect where revenue grows faster than costs, expanding margins. It also sourced 71 per cent of materials domestically and now manufactures over 90 per cent of its advanced intermediates in-house, reducing its exposure to the kind of external supply shock that hurt it in FY24.

The big bet

The anchor of the CDMO business is Fermion, a Finnish company that manufactures the active ingredient for Darolutamide, a cancer drug sold by Bayer. This single contract accounts for the majority of CDMO revenue, with one-third of Acutaas's Ankleshwar facility dedicated to it. The relationship has deepened to cover five intermediates, with patent protection running to 2033–2035 in most geographies.

The Rs 310 crore Ankleshwar facility was built around this pipeline. Management targets three times asset turnover, meaning every rupee of plant investment should eventually generate three rupees in annual revenue, implying roughly Rs 930 crore at full utilisation. Getting there requires far more than one contract.

The Rs 1,000 crore FY28 target rests on several CDMO relationships. A deal with another large European originator is in final negotiation. Further behind sits a pipeline of 60 to 80 molecules currently in clinical trials, with several nearing approval and expected to contribute revenue between FY27 and FY29.

The risks that matter

Start with the Fermion dependency. Revenue from this contract depends entirely on Bayer's prescription volumes, pricing decisions and the competition Darolutamide faces in the market, none of which Acutaas controls. And with patents running to 2033–2035, the question of what happens when cheaper generic versions eventually enter is one the company has not yet had to answer.

Then there is the growth target itself. CDMO revenue needs to roughly double, two years in a row. Only one of Ankleshwar's three production blocks has been fully commercialised, and even that runs at 50-60 per cent utilisation. A large part of the pipeline must still clear regulatory approvals and secure launch decisions within the FY28 window. The company already trimmed guidance once in Q2 FY23 when a customer delayed a launch, normal in this industry, but the FY28 target leaves very little room for such delays.

Beneath all of this sits the generics business, with no long-term contract cover. China has a pattern of cutting ingredient prices by 40-50 per cent to defend market share. Without contracts to cushion the blow, Acutaas absorbs that pressure in full.

Priced for everything to go right

Acutaas trades at 60 times its trailing earnings, the profits it has actually delivered over the past year. For context, peers Neuland and Divi's trade at 86 and 62 times, respectively, but both earned those multiples through years of demonstrated execution. Acutaas is commanding the valuation of a proven CDMO player while still becoming one.

Here is the simplest way to think about what today's price demands. For an investor to earn a 15 per cent annual return over five years, Acutaas's profits need to grow at 25 per cent every year, and that assumes the valuation multiple compresses from 60 times to a still-generous 40 times. If growth slips to 20 per cent annually, the return falls to just 10 per cent.

That asymmetry is the problem. The CDMO pivot is real. The Fermion contract is solid. The margin recovery is not a fluke. But the stock has already priced in all of that, and then some. Any delay in regulatory approvals, any slowdown in the CDMO ramp, any contract that takes longer to close than expected, and the valuation shrinks sharply. The business is in the middle of a genuine transformation. The stock, unfortunately, is already priced as though that transformation is complete.

Knowing when a compelling story has already been priced in, and when it hasn't, is precisely the kind of call that separates disciplined investing from expensive enthusiasm. Value Research Stock Advisor tracks businesses through their transformation, not just at the moment they make headlines, so you know whether the opportunity is still open or already in the price.

Join Stock Advisor